PRESTO 2: An International Survey to Evaluate Patients’ Injection Experiences with the Latest Devices/Formulations of Long-Acting Somatostatin Analog Therapies for Neuroendocrine Tumors or Acromegaly
O’Toole D, Kunz P, Webb S, Goldstein G, Khawaja S, McDonnell M, Boiziau S, Gueguen D, Houchard A, Ribeiro-Oliveira A, Prebtani A. PRESTO 2: An International Survey to Evaluate Patients’ Injection Experiences with the Latest Devices/Formulations of Long-Acting Somatostatin Analog Therapies for Neuroendocrine Tumors or Acromegaly. Advances In Therapy 2022, 40: 671-690. PMID: 36502449, PMCID: PMC9741754, DOI: 10.1007/s12325-022-02360-6.Peer-Reviewed Original ResearchConceptsInjection site painNeuroendocrine tumorsInjection experienceRecent injectionLanreotide autogel/depotMultivariate logistic regression modelOdds of painSomatostatin analogue therapyProportion of patientsInjection site reactionsLogistic regression modelsSSA useAnalogue therapySecondary endpointsDisease subgroupsPainPatientsAcromegalyInjection modalitiesMonthsInjectionTumorsPMON57 Impact of Injection Modalities on Real-World Injection Experience in Patients with Acromegaly or Neuroendocrine Tumors (NETs) Treated With Somatostatin Analog (SSA) Therapy: Data from the PRESTO 2 Survey
Ribeiro-Oliveira A, O’toole D, Kunz P, Houchard A, Boiziau S, Prebtani A, Webb S. PMON57 Impact of Injection Modalities on Real-World Injection Experience in Patients with Acromegaly or Neuroendocrine Tumors (NETs) Treated With Somatostatin Analog (SSA) Therapy: Data from the PRESTO 2 Survey. Journal Of The Endocrine Society 2022, 6: a557-a557. PMCID: PMC9625390, DOI: 10.1210/jendso/bvac150.1157.Peer-Reviewed Original ResearchInjection site painNeuroendocrine tumorsInjection experiencePrimary endpointLast doseLast injectionLanreotide autogel/depotFirst-line medical treatmentInjection modalitiesMultivariate logistic regression analysisOdds of painProportion of patientsSomatostatin analogue therapyInjection site reactionsLogistic regression analysisSecondary endpointsAnalogue therapySSA therapyDisease groupPainMedical treatmentPatientsAcromegalyInjection siteEndpointReal-world injection experience and use of independent injection among patients using lanreotide autogel/depot (LAN) prefilled syringe or octreotide long-acting release (OCT) to treat acromegaly or neuroendocrine tumors (NETs): international PRESTO 2 survey
Webb S, O'Toole D, Kunz P, Houchard A, Boiziau S, Ribeiro-Oliveira A, Prebtani A. Real-world injection experience and use of independent injection among patients using lanreotide autogel/depot (LAN) prefilled syringe or octreotide long-acting release (OCT) to treat acromegaly or neuroendocrine tumors (NETs): international PRESTO 2 survey. Endocrine Abstracts 2022 DOI: 10.1530/endoabs.81.oc4.5.Peer-Reviewed Original Research